Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?

Tsoulas, Christos; Nathwani, Dilip

doi:10.1016/j.ijantimicag.2015.03.011

Cited by 24 publications

(25 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, telavancin is associated with a greater number of severe adverse effects and also bears the risk of nephrotoxicity; daptomycin may lead to an increase in CK levels; and linezolid may cause thrombocytopenia. Based on the (comparative) studies available, there is currently no reason to generally prefer the newer substances over vancomycin .…”

Section: Introductionmentioning

confidence: 99%

“…However, the percentage of LA‐MRSA (in relation to all MRSA strains) may be significantly higher in regions with intensive livestock farming (Northwest Germany) . ▸ First‐line agent : linezolid OR daptomycin , ▸ Second‐line agent, or if the aforementioned antibiotics are not effective : vancomycin plus a combination partner (rifampicin or fosfomycin or fusidic acid).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

S2k guidelines for skin and soft tissue infections Excerpts from the S2k guidelines for “calculated initial parenteral treatment of bacterial infections in adults – update 2018“

Sunderkötter

Becker

Eckmann³

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDiese erste deutschsprachige S2k-Leitlinie zu bakteriellen Haut-und Weichgewebeinfektionen ist im Rahmen der "Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen" unter Federführung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. entstanden und wird in wichtigen Auszügen hier wiedergegeben.Voraussetzung für gut kalkulierte Antibiotikatherapien ist eine genaue diagnostische Zuordnung. So wird das Erysipel definiert als nichteitrige Infektion als deren Erreger β -hämolysierende Streptokokken gelten, und das klinisch diagnostiziert wird

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

S2k guidelines for skin and soft tissue infections Excerpts from the S2k guidelines for “calculated initial parenteral treatment of bacterial infections in adults – update 2018“

Sunderkötter

Becker

Eckmann³

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…En el metaanálisis de Bally y cols, al evaluar los estudios que incluían pacientes hospitalizados con IPTB complicadas causadas por SAMR no encontraron diferencia en la tasa de respuesta clínica de tigeciclina al compararla con vancomicina OR 0,89 (IC95%0,61-1,27) 22 . De igual forma Tsoulas en una revisión de los metaanálisis publicados sobre el tratamiento de infecciones de piel y tejidos blandos por SAMR evidencia similar tasa de eficacia clínica y microbiológica al compararla con vancomicina 32 . Heizmann encontró una tasa de éxito en el tratamiento de 94% en IPTB complicadas causadas por SAMR tratadas con tigeciclina 33 .…”

Section: Uso De Tigeciclina En El Manejo De Infecciones De Piel Y Tejunclassified

Tigeciclina en infecciones de piel y tejidos blandos complicadas.

Rodríguez¹,

Valderrama

Roncancio-Villamil

et al. 2017

Infect

View full text Add to dashboard Cite

ResumenObjetivo: evaluar la mejor evidencia actual disponible para generar recomendaciones con respecto a la efectividad y seguridad del uso de tigeciclina en adultos con infección de piel y tejidos blandos (IPTB). Materiales y métodos: se realizó una revisión sistemática de la literatura, seleccionando los metaanálisis y experimentos clínicos controlados (ECCs), los cuales se valoraron utilizando la herramienta SIGN (Scottish Intercollegiate Guidelines Network.), con el fin de generar tablas de evidencia según GRADE de los estudios de tigeciclina en la indicación de IPTB, para posteriormente utilizar un proceso Delphi modificado para calificar las diferentes recomendaciones. Resultados: la revisión sistemática se incluyeron 9 metaanálisis que incluyeron 5 estudios clínicos aleatorizados con 1873 pacientes, y de ellos 952 asignados al brazo de tigeciclina, no mostró inferioridad frente a los comparadores en curación clínica (RR= 0.76 IC95% 0,57 -1.03), curación microbiológica (RR= 0.92 IC95% 0,61 -1.38), eventos adversos serios RR 1,41 (IC95%0,97 a 2,35), ni mortalidad RR 1,9 (IC95%0,84 a 4,3). La tigeciclina puede relacionarse con mayor frecuencia de eventos adversos leves de origen gastrointestinal. Conclusión: en pacientes adultos con IPTB, se considera que el uso de tigeciclina en monoterapia en pacientes no críticamente enfermos es equivalente en eficacia a otras opciones terapéuticas antimicrobianas. Se debe considerar especialmente como terapia de ajuste en pacientes con infecciones polimicrobianas.Palabras claves: Tigeciclina, metaanálisis, infección de piel y tejidos blandos, infecciones bacterianas de la piel. Tigecycline in complicated skin and soft-tissue infection AbstractObjective: To assess current best evidence available to generate recommendations regarding the effectiveness and safety of tigecycline use in adults with skin and soft-tissue infections (SSTIs). Materials and methods: A systematic review of the literature was conducted by selecting meta-analyzes and controlled clinical trials (CCTs), which were assessed using the SIGN tool (Scottish Intercollegiate Guidelines Network) in order to generate evidence tables according to GRADE of studies of tigecycline in the SSTIs indication, and then using a modified Delphi Method to score the different recommendations. Results: Nine meta-analyzes were included compounded by five randomized clinical trials with a sample size of 1873 patients, where 952 patients were assigned to tigecycline. The group of patients with tigecycline showed no inferiority to the comparator in clinical cure (RR = 0.76 95% CI 0.57 -1.03), microbiologic cure (RR = 0.92 95% CI 0.61 -1.38), serious adverse events RR 1, 41 (95% CI 0.97 to 2.35) or mortality RR 1.9 (95% CI 0.84 to 4.3). Tigecycline may be related to increased frequency of minor adverse events of gastrointestinal origin. Conclusion: In adult patients with SSTIs, it is considered that the use of tigecycline in monotherapy in non-critically ill patients is equivalent in effectiveness to other antimicrobial treatmen...

show abstract

“…39 Alternative gram-positive therapies such asceftaroline, daptomycin, dalbvancin, oritavancin, and tedizolid also offer possible prospects for treatment of infections with MDRO gram-positive organisms. 40 …”

Section: Dumford III and Skalweitmentioning

confidence: 99%

Antibiotic-Resistant Infections and Treatment Challenges in the Immunocompromised Host

Dumford

Skalweit

2016

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?

Cited by 24 publications

References 38 publications

S2k guidelines for skin and soft tissue infections Excerpts from the S2k guidelines for “calculated initial parenteral treatment of bacterial infections in adults – update 2018“

S2k guidelines for skin and soft tissue infections Excerpts from the S2k guidelines for “calculated initial parenteral treatment of bacterial infections in adults – update 2018“

Tigeciclina en infecciones de piel y tejidos blandos complicadas.

Antibiotic-Resistant Infections and Treatment Challenges in the Immunocompromised Host

Contact Info

Product

Resources

About